ALTOPREV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Altoprev, and what generic alternatives are available?
Altoprev is a drug marketed by Covis and is included in one NDA.
The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Altoprev
A generic version of ALTOPREV was approved as lovastatin by ACTAVIS ELIZABETH on December 17th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALTOPREV?
- What are the global sales for ALTOPREV?
- What is Average Wholesale Price for ALTOPREV?
Summary for ALTOPREV
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 126 |
| Clinical Trials: | 6 |
| Drug Prices: | Drug price information for ALTOPREV |
| What excipients (inactive ingredients) are in ALTOPREV? | ALTOPREV excipients list |
| DailyMed Link: | ALTOPREV at DailyMed |
Recent Clinical Trials for ALTOPREV
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Brigham and Women's Hospital | Phase 4 |
| Amgen | Phase 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
Pharmacology for ALTOPREV
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
US Patents and Regulatory Information for ALTOPREV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-004 | Jun 26, 2002 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-002 | Jun 26, 2002 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-003 | Jun 26, 2002 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALTOPREV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-004 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-002 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-002 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-003 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-003 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-003 | Jun 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALTOPREV
See the table below for patents covering ALTOPREV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2390301 | ⤷ Sign Up | |
| Australia | 737962 | ⤷ Sign Up | |
| Canada | 2315329 | PREPARATION AMELIOREE D'INHIBITEURS DE LA HMG COA REDUCTASE A LIBERATION ETENDUE (IMPROVED HMG COA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION) | ⤷ Sign Up |
| Australia | 1360701 | ⤷ Sign Up | |
| Spain | 2252872 | ⤷ Sign Up | |
| Australia | 1627599 | ⤷ Sign Up | |
| European Patent Office | 1063980 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
